FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ALECENSA (alectinib hydrochloride) filed by Genentech, Inc., authorizing changes to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)

Snippet

SUPPL AP for ALECENSA (ALECTINIB HYDROCHLORIDE)